Stock Code: 300765
Stock Abbreviation: CStone Pharma
Announcement Number: 2026-061
CStone Pharmaceuticals Co., Ltd.
Announcement on Inclusion of SYS6043, a Subsidiary's Product, in the Breakthrough Therapy List for the Treatment of Patients with Platinum-Resistant Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer
The Company and all members of the Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, and contains no false records, misleading statements, or major omissions.
Overview
The injectable drug SYS6043, developed by CStone Group Giant Biologics Co., Ltd. (hereinafter referred to as "Giant Biologics"), a subsidiary of CStone Pharmaceuticals Co., Ltd. (hereinafter referred to as the "Company"), has been included in the Breakthrough Therapy list by the Center for Drug Evaluation (hereinafter referred to as the "CDE") of the National Medical Products Administration. The relevant situation is hereby announced as follows: